scholarly journals Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma

2020 ◽  
Vol 3 ◽  
pp. 7-7
Author(s):  
Mengni He ◽  
MacKenzie Henderson ◽  
Stephen Muth ◽  
Adrian Murphy ◽  
Lei Zheng
Keyword(s):  
Drug Development ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Mouse Models ◽  
Ductal Adenocarcinoma

scholarly journals Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma

2021 ◽  
Vol 14 (3) ◽  
pp. 280
Author(s):  
Rita Rebelo ◽  
Bárbara Polónia ◽  
Lúcio Lara Santos ◽  
M. Helena Vasconcelos ◽  
Cristina P. R. Xavier
Keyword(s):  
Clinical Trials ◽  
Drug Development ◽  
Pancreatic Ductal Adenocarcinoma ◽  
De Novo ◽  
Drug Repurposing ◽  
Metastatic Tumor ◽  
Therapeutic Options ◽  
Ductal Adenocarcinoma ◽  
Clinical Indication ◽  
Novel Treatments

Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy remaining the basis of systemic therapy. However, no major advances have been made recently, and therapeutic options are limited and highly toxic. Thus, novel therapeutic options are urgently needed. Drug repurposing is a strategy for the development of novel treatments using approved or investigational drugs outside the scope of the original clinical indication. Since repurposed drugs have already completed several stages of the drug development process, a broad range of data is already available. Thus, when compared with de novo drug development, drug repurposing is time-efficient, inexpensive and has less risk of failure in future clinical trials. Several repurposing candidates have been investigated in the past years for the treatment of PDAC, as single agents or in combination with conventional chemotherapy. This review gives an overview of the main drugs that have been investigated as repurposing candidates, for the potential treatment of PDAC, in preclinical studies and clinical trials.

scholarly journals MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus

2018 ◽  
Vol 9 (6) ◽  
Author(s):  
Jack D. Godfrey ◽  
Jennifer P. Morton ◽  
Ania Wilczynska ◽  
Owen J. Sansom ◽  
Martin D. Bushell
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Mouse Models ◽  
Mutant Mouse ◽  
Ductal Adenocarcinoma

Coaxing cancer control by modulating COX-2

2019 ◽  
Vol 11 (497) ◽  
pp. eaax9566 ◽  
Author(s):  
Rajan P. Kulkarni
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Mouse Models ◽  
Cancer Control ◽  
Cyclooxygenase 2 ◽  
Ductal Adenocarcinoma ◽  
Cox 2

Mouse models of pancreatic ductal adenocarcinoma respond to immunotherapy when given in combination with the cyclooxygenase-2 inhibitor celecoxib.

Sign in / Sign up

Export Citation Format

Share Document